Introduction {#S1}
============

Steady oxygen supply is the basic requirement for humans to survive. However, intermittent hypoxic ([@B23]) or ischemic ([@B10]) conditions are often applied to trigger therapeutic adaptions in a variety of clinical diseases and emotional disorders. remote ischemic preconditioning (RIPC) are short episodes of non-fatal ischemia followed by reperfusion, usually applied to remote tissue for the purpose of protecting a specific organ or cardiovascular bed from future (preconditioning) or past (postconditioning) ischemic stimuli ([@B25]; [@B10]; [@B11]). The signaling pathways are not completely understood so far but it involves neuronal, humoral, and systemic pathways ([@B9]; [@B7]; [@B10]; [@B1]). RIPC can easily performed non-invasively in clinical practice by inflating and deflating a blood-pressure cuff on the upper arm or thigh, to induce transient ischemia, and reperfusion.

The idea of RIPC was originally to protect from myocardial injury during coronary artery bypass grafting first shown in 1993 ([@B22]). In the subsequent years, many other experimental studies have also shown promising results ([@B8]). Although a large randomized-controlled trial refuted previous findings recently ([@B7]), there are many other protective effects of organs other than the heart reported for RIPC ([@B4]). One significant is the endothelium, the inner cell layer of the vasculature which regulates vascular tone. Studies already pointed out that repeated RIPC improve endothelium-dependent vasodilation or protect endothelial function from ischemic injury ([@B16]; [@B14]; [@B20]; [@B2]; [@B12], [@B13]; [@B6]). Since endothelial function regulates vascular tone, it is also a key component to determine arterial stiffness and blood pressure (BP). However, there are only few studies directly assessing BP and arterial stiffness in the context of RIPC bearing controversial findings. [@B14] found no altered BP after 4-weeks of daily RIPC even though endothelium-dependent vasodilation improved. In addition, [@B13] could not find BP changes after 8-weeks of three times RIPC per week. Other small reports ([@B12]; [@B6]; [@B21]) and case studies ([@B18]; [@B17]) on the contrary found improved BP due to repeated RIPC exposure and there is only one study ([@B29]) aiming at arterial stiffness and RIPC in patients with angina pectoris.

Overall, the short-term effect of RIPC on BP, heart rate, and arterial stiffness is unknown. Therefore, the aim of this study was to evaluate whether a single RIPC procedure shows a short-term improvement of BP and arterial stiffness.

Patients and Methods {#S2}
====================

Study Design and Subjects {#S2.SS1}
-------------------------

From March 2018 to August 2018, we included 40 healthy volunteers without cardiovascular disease (23 female, age 25.6 ± 2.8 years, [Table 1](#T1){ref-type="table"}) into this single blinded randomized-controlled trial. Participants had no chronical diseases or acute infection during the study period. For standardization, all measurements were performed during 8:00 to 10:00 a.m. in the morning. The participants were free of infections, sober and did not consume any alcohol or tobacco for the last 12 h.

###### 

Baseline characteristics of participants (*n* = 40).

  ---------------------------------------- -------------
  **Anthropometrics**                      
  Gender (female)                          23 (57.5%)
  Age (years)                              25.6 ± 2.8
  Height (cm)                              173.3 ± 9.7
  Weight (kg)                              65.5 ± 10.9
  BMI (kg/m^2^)                            21.7 ± 2.3
  **Blood pressure and heart rate**        
  Heart rate (beats/min)                   66.5 ± 9.1
  Systolic blood pressure (mmHg)           118.1 ± 8.8
  Diastolic blood pressure (mmHg)          71.7 ± 6.5
  **Arterial stiffness**                   
  Central systolic blood pressure (mmHg)   111.2 ± 9.9
  Pulse wave velocity (m/s)                5.18 ± 0.37
  ---------------------------------------- -------------

After resting for 5 min in supine position the participants received a BP, heart rate, and arterial stiffness measurement on the left upper arm using oscillometric measurement device Mobil-O-Graph^®^ (IEM Healthcare, Stolberg Germany). Afterward they were randomized into an intervention or SHAM group using block method. The intervention group received a RIPC protocol of 3 cycles of 5 min each with occlusion to 200 mmHg with a special BP cuff on the right thigh followed by 5 min re-perfusion. The SHAM procedure consisted of a pressure cuff, inflated on the right upper arm for the same periods as the RIPC intervention but only to 40 mmHg as it has shown to mimic occlusion but not limiting blood flow. The study participants were thus led to believe that this study was a comparison between different occlusion techniques on the thigh and upper arm.

Directly after this 30-min intervention or SHAM a reassessment of BP, heart rate and arterial stiffness measures was conducted. After a mean of 6.8 ± 1.0 days a crossover was performed and participants assigned to the other group and underwent the procedure again ([Figure 1](#F1){ref-type="fig"}).

![Study Protocol. RIPC, remote ischemic preconditioning.](fphys-10-01094-g001){#F1}

The study was conducted in accordance with the Declaration of Helsinki (revision 2008) and the Good Clinical Practice guidelines. The study protocol was approved by the local ethical board (project number 209/18S) of the Technical University Munich. All participants gave written informed consent and agreed to anonymous publication of their data.

Blood Pressure, Heart Rate, and Arterial Stiffness Measurement {#S2.SS2}
--------------------------------------------------------------

Blood pressure and arterial stiffness were automatically measured on the left upper arm with the oscillometric cuff-based Mobil-O-Graph device in a supine position after 5 min rest. Cuffs were chosen according to the circumference of the left upper arm ([@B5]; [@B19]).

Central systolic blood pressure and pulse wave velocity (PWV) were indirectly estimated with an ARCSolver Algorithmus (Austrian Institute of Technology, Vienna, Austria) based on the recorded brachial pulse waves. This method includes the influence of arterial impedance and the aortic hemodynamics using a generalized transfer function and a mathematical model. It is confirmed that this non-invasive cuff-based method of the Mobil-O-Graph strongly correlates with the invasive measurement of central BP ([@B27]; [@B28]; [@B24]).

Data Analyses {#S2.SS3}
-------------

Data is described by mean ± standard deviation for all variables after proving normality for systolic, diastolic, central BP, and PWV by a Kolmogorov Smirnov test. To measure the effect of RIPC, differences between baseline and post-tests were calculated for intervention and SHAM procedures. Afterward the differences were compared with Student's *t*-test for independent samples.

All tests were performed using SPSS (version 23.0, IBM Corporation). The level of significance for all two-tailed tests was set to \<0.050.

Results {#S3}
=======

There were no significant changes and very low effect sizes in all of the four outcome parameters when comparing the effect of RIPC to SHAM.

As shown in [Table 2](#T2){ref-type="table"}, in peripheral systolic BP the mean difference between groups was Δ1.14 ± 6.5 mmHg (effect size eta: 0.048; *p* = 0.672), and for diastolic BP Δ−0.69 ± 4.5 mmHg (effect size eta: 0.075; *p* = 0.507). There was also no significant change in heart rate (Δ−0.8 ± 4.7 beats/min; *p* = 0.397).

###### 

Blood pressure and atrial stiffness parameters according to intervention and SHAM group.

                                           **Intervention group**   **SHAM group**   **Effect**                                                                       
  ---------------------------------------- ------------------------ ---------------- ------------- -------------- -------------- -------------- ------------- ------- -------
  **Blood pressure**                                                                                                                                                  
  Heart rate (beats/min)                   66.5 ± 9.1               60.6 ± 7.4       −5.9 ± 5.1    65.8 ± 8.3     60.7 ± 6.2     −5.1 ± 4.6     −0.8 ± 4.7    0.090   0.397
  Systolic blood pressure (mmHg)           118.1 ± 8.7              119.5 ± 10.5     1.45 ± 7.1    117.9 ± 11.6   118.8 ± 11.0   0.83 ± 6.01    1.14 ± 6.5    0.048   0.672
  Diastolic blood pressure (mmHg)          71.7 ± 6.5               70.7 ± 6.9       −1.03 ± 4.8   71.7 ± 7.2     71.4 ± 7.1     −0.35 ± 4.19   −0.69 ± 4.5   0.075   0.507
  **Arterial stiffness**                                                                                                                                              
  Central systolic blood pressure (mmHg)   111.2 ± 9.9              111.7 ± 10.5     0.45 ± 7.3    111.3 ± 10.5   111.6 ± 11.5   0.35 ± 7.26    0.40 ± 7.2    0.007   0.951
  Pulse wave velocity (m/s)                5.18 ± 0.37              5.21 ± 0.41      0.03 ± 0.27   5.21 ± 0.43    5.20 ± 0.45    −0.01 ± 0.26   0.01 ± 0.26   0.066   0.563

Regarding arterial stiffness measures there were also no significant improvements through RIPC. The mean difference between RIPC and SHAM for central systolic BP was Δ0.40 ± 7.2 mmHg (eta: 0.007; *p* = 0.951) and for PWV Δ0.01 ± 0.26 m/s (eta: 0.066; *p* = 0.563).

Moreover, there were also no significant changes in systolic BP, diastolic BP, central systolic BP and PWV when comparing pre-RIPC with post-RIPC, and pre-SHAM with post-SHAM ([Table 2](#T2){ref-type="table"}, all *p* \> 0.189). Only heart rate deceased in pre-RIPC with post-RIPC and pre-SHAM with post-SHAM significantly (both *p* \< 0.001).

Discussion {#S4}
==========

This study could not find any short-term effects of RIPC on BP, heart rate, and arterial stiffness in a randomized controlled trial with a crossover design in a big sample of 40 young healthy participants.

Remote ischemic preconditioning was originally designed to prevent the myocardium from subset ischemia during coronary artery bypass grafting ([@B22]). There were studies showing promising results early on ([@B8]), but bigger studies and randomized controlled trials have meanwhile cast doubt on the subject ([@B7]). Nevertheless, there is compelling evidence measured mostly in the context of flow-mediated dilation that RIPC improves endothelial function ([@B14]; [@B12], [@B13]) and prevents the endothelial from injury during ischemia ([@B16]). Improvement or conservation of vascular function is a central feature because it reduces the risk for cardiovascular disease ([@B26]).

In addition to endothelial function, some studies assessed BP response to RIPC with controversial findings. In two different studies [@B12], [@B13] observed contradicting results in regard to different RIPC protocols. In the study with BP lowering effect they applied RIPC over seven consecutive days ([@B12]), whereas when using a protocol of just three times RIPC per week over a 8 week intervention period the BP lowering effect diminished ([@B13]). In the latter, they suggested that the lower stimuli have been of insufficient frequency to induce adaption in the cutaneous circulation. However, if the lower stimuli would be the reason in the second study ([@B13]), the study from [@B14] in which six single bouts of RIPC were performed daily over a period of 1 month should also have led to a drop in BP; but did not. The same is true for the study of [@B3] where a 9-day RIPC period had also no effects. However, all the studies ([@B14]; [@B12], [@B13]; [@B3]) looked on normotensive and young participants and where BP lowering effects are hardly occur (floor effect). They also did not enable 24-h BP monitoring that would have brought more insights of the effect because RIPC has two phases; an early (up to 4 h) and late (after 24 h) ([@B16]). Especially on these two phases further studies should be aimed at in order to measure possible effects also on normotensive persons. Further it is still not clear which RIPC protocol is the most effective. Especially if one considers that a RIPC intervention with healthy vessels may have to be designed quite differently than in patients. Moreover. all of the studies including ours neglected hemodynamic conditions and loading conditions that have an important influence on BP. To mention at least heart rate that was similar pre SHAM and RIPC in our study and declined in parallel at post conditions which makes a possible bias unlikely.

On the other hand, in patients with chronic ischemic heart failure a 4-week RIPC program tended to improved systolic BP ([@B21]) and it can therefore be assumed that the effect of RIPC is more pronounced when vascular health is already decreased. The same occurred in the study from [@B29] where the improved endothelial compliance and a reduction in peripheral systolic BP was outlined only in patients with angina pectoris although their RIPC protocol, which was similar to ours, consisted of only one RIPC of 3 × 5 min. Nevertheless the stimuli seem to be sufficient to trigger the humoral and neuronal mechanisms that mediate the endothelium by means of the sympathetic and parasympathtic nervous systems ([@B9]; [@B10]; [@B29]; [@B11]). The merit of this study ([@B29]) is that it is the only one which has investigated arterial stiffness using central systolic BP, which was also reduced after RIPC only in the angina pectoris group. Especially in hypertensive patients or patients with cardiovascular diseases, future studies must therefore be based on repeated RIPC exposure and focus on long-term assessment. Unfortunately, there are no other reports available that have investigated arterial stiffness measures like PWV, augmentation index or even the central BP in the context of RIPC. As endothelial function, arterial stiffness is also a subtle marker of arteriosclerosis. Therefore, changes in vascular tone mediated by the endothelium should come to light when assessing in arterial stiffness parameters ([@B15]). In our healthy population, we assume that the single stimulus is not enough to trigger mechanisms that improve arterial stiffness. When we consider the relatively large number of cases in the present study then one can almost certainly say that a single RIPC has no short-term effect on BP and arterial stiffness in young healthy adults.

Conclusion {#S5}
==========

This study could not find any short-term effects of RIPC on arterial stiffness and BP in a randomized controlled trial with a crossover design in a big sample of 40 young and healthy adults. Whether these findings also apply to patients with cardiovascular diseases must be clarified in further studies. Therefore, protocols have to be optimized with regard to duration and frequency of ischemia and reperfusion and the underlying mechanisms of RIPC have to be better understood ([@B10]).

Limitations {#S6}
===========

The study suffers from few volunteers and on higher number of cases should be aimed in further studies in order to take account of the high standard deviations in BP. Arterial stiffness and BP were recorded only once. For a more detailed BP analysis, multiple (favorable three) measures should be performed to determine BP, and arterial stiffness. However, it should be considered that multiple pre- and post- BP assessments are also short bouts of RIPC and could therefore bias the data. The use of our oscillometric device for the assessment of arterial stiffness utilizes cuff inflation to measure PWV and central pressure and thus adds an ischemic stimuli to the sham group and an additional ischemic stimuli to the intervention group. Devices using applanation tonometry would be more appropriate for this study.
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